Q Therapeutic System for Chronic Stroke Recovery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorBurke Rehabilitation Hospital
About this trial
Evaluate the effectiveness of the Q Therapeutic (BQ 3.0) System for individuals with chronic stroke in improving upper extremity function as determined by change in functional outcome measures after 3-month treatment, including in-clinic and at-home sessions.
Eligibility criteria
Qualifiers
FMA-UE score between 22-50 (inclusive) of impaired limb.
Difference between Screening and Baseline visit FMA-UE is 3 points or fewer.
Age 18 to 80 years of age (inclusive).
Stroke due to ischemia or to intracerebral hemorrhage.
Disqualifiers
Severe neglect impairment interfering with assessments or treatments.
Severe depression, defined as GDS Score >10/15
The presence of MR-incompatible implanted devices or MR-incompatible retained objects; or the presence of life-sustaining MR-compatible devices (e.g. pacemaker or internal cardiac defibrillator).
Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
Trial design
Treatments tested in this trial
- Q Therapeutic System (BQ 3.0) - Active
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Burke Rehabilitation Hospital
Lead sponsor
BrainQ Technologies Ltd.
Collaborator
Source ClinicalTrials.gov